AU2001281798A1 - Bioisosteric benzamide derivatives and their use as apob-100 secretion inhibitors - Google Patents

Bioisosteric benzamide derivatives and their use as apob-100 secretion inhibitors

Info

Publication number
AU2001281798A1
AU2001281798A1 AU2001281798A AU8179801A AU2001281798A1 AU 2001281798 A1 AU2001281798 A1 AU 2001281798A1 AU 2001281798 A AU2001281798 A AU 2001281798A AU 8179801 A AU8179801 A AU 8179801A AU 2001281798 A1 AU2001281798 A1 AU 2001281798A1
Authority
AU
Australia
Prior art keywords
bioisosteric
apob
benzamide derivatives
secretion inhibitors
secretion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001281798A
Other languages
English (en)
Inventor
Nerina Dodic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2001281798A1 publication Critical patent/AU2001281798A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
AU2001281798A 2000-06-01 2001-06-01 Bioisosteric benzamide derivatives and their use as apob-100 secretion inhibitors Abandoned AU2001281798A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0013383 2000-06-01
GBGB0013383.5A GB0013383D0 (en) 2000-06-01 2000-06-01 Therapeutic benzamide derivatives
PCT/EP2001/006243 WO2001096327A1 (en) 2000-06-01 2001-06-01 BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APoB-100 SECRETION INHIBITORS

Publications (1)

Publication Number Publication Date
AU2001281798A1 true AU2001281798A1 (en) 2001-12-24

Family

ID=9892825

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001281798A Abandoned AU2001281798A1 (en) 2000-06-01 2001-06-01 Bioisosteric benzamide derivatives and their use as apob-100 secretion inhibitors

Country Status (6)

Country Link
US (1) US20040009988A1 (ja)
EP (1) EP1289982A1 (ja)
JP (1) JP2004503549A (ja)
AU (1) AU2001281798A1 (ja)
GB (1) GB0013383D0 (ja)
WO (1) WO2001096327A1 (ja)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002338537A (ja) * 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
AU2002307839B2 (en) 2001-06-28 2006-03-16 Zoetis P Llc Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
UA79300C2 (en) * 2002-08-12 2007-06-11 Janssen Pharmaceutica Nv N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
ATE556056T1 (de) 2003-07-29 2012-05-15 Xenon Pharmaceuticals Inc Pyridylderivate und deren verwendung als therapeutische mittel
NZ545265A (en) 2003-07-30 2009-11-27 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use for treating diseases mediated by stearoyl-CoA desaturase (SCD) enzymes
KR20060036106A (ko) * 2003-07-30 2006-04-27 제논 파마슈티칼스 인크. 피리딜 유도체 및 그의 치료제로서의 용도
SG145701A1 (en) 2003-07-30 2008-09-29 Xenon Pharmaceuticals Inc Piperazine derivatives and their use as therapeutic agents
UA83510C2 (en) * 2003-12-09 2008-07-25 Янссен Фармацевтика Н.В. N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b
EP1751131B1 (en) * 2004-03-10 2008-11-19 Janssen Pharmaceutica N.V. Mtp inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles
DE602005011127D1 (de) * 2004-03-10 2009-01-02 Janssen Pharmaceutica Nv Durch 5gliedrige heterocyclen substituierte mtp-inhibierende arylpiperidine oder -piperazine
US20080167321A1 (en) 2004-09-20 2008-07-10 Xenon Pharmaceuticals Inc. Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase
MX2007003321A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
WO2006034440A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
US7592343B2 (en) 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
AU2005311534B2 (en) 2004-12-03 2011-02-17 F. Hoffmann-La Roche Ag 3-substituted pyridine derivatives as H3 antagonists
CN101208089A (zh) 2005-06-03 2008-06-25 泽农医药公司 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
US7683058B2 (en) * 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
BRPI0817211A2 (pt) 2007-09-20 2017-05-16 Irm Llc composto composições como moduladores da atividade de gpr119
EP3006031A1 (en) 2009-02-05 2016-04-13 Takeda Pharmaceutical Company Limited Pyridazinone compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
WO1996040640A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
YU23499A (sh) * 1996-11-27 2001-07-10 Pfizer Inc. Inhibitorski amidi apo-b-sekrecije/mtp-a
WO1998027979A1 (en) * 1996-12-20 1998-07-02 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
WO2001053260A1 (en) * 2000-01-18 2001-07-26 Novartis Ag Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion

Also Published As

Publication number Publication date
WO2001096327A1 (en) 2001-12-20
US20040009988A1 (en) 2004-01-15
GB0013383D0 (en) 2000-07-26
JP2004503549A (ja) 2004-02-05
EP1289982A1 (en) 2003-03-12

Similar Documents

Publication Publication Date Title
AU2001281798A1 (en) Bioisosteric benzamide derivatives and their use as apob-100 secretion inhibitors
PL348042A1 (en) Benzamide derivatives and their use as apob-100 secretion inhibitors
HK1057214A1 (en) New mandelic acid derivatives and their use as throbin inhibitors
AU2001249969A1 (en) Inha inhibitors and their use as antibacterials
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
AU2001240542A1 (en) Heterocyclic compounds and their use as parp inhibitors
IL157659A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
AU2001244399A1 (en) Gamma-secretase inhibitors
AU2001249670A1 (en) Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
AU2003302919A1 (en) Pyridine derivatives as jnk inhibitors and their use
GB0025782D0 (en) Use of inhibitors
AU2001270260A1 (en) 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
AU2002361861A1 (en) SELECTIVE 11Beta-HSD INHIBITORS AND METHODS FOR USE THEREOF
AU2002230836A1 (en) Benzylamine derivatives and their use as thrombin inhibitors
AU2003232848A1 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU2001281799A1 (en) Benzamide derivatives and their use as apob-100 and mtp inhibitors
IL143987A0 (en) New amidinobenzylamine derivatives and their use as thrombin inhibitors
IL152396A0 (en) New thiochromane derivatives derivatives and their use as thrombin inhibitors
AU2003258942A1 (en) Imidazolidinedione-derivatives and their use as metalloproteinase inhibitors
AU2001277561A1 (en) Biphenyl derivatives and the use thereof as integrin inhibitors
AU2001266124A1 (en) 2-aminothiazoline derivatives and their use as no-synthase inhibitors
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
AU2003218715A1 (en) Azepane derivatives and their use as atk1 inhibitors
AU2001259626A1 (en) Indole derivatives and their use as 15-lipoxygenase inhibitors